Jean-Baptiste Micol

List of Publications by Year
in descending order

58	2,945	279487 23	174990 52
papers	citations	h-index	g-index

59	59	59	5972
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. Leukemia, 2022, 36, 126-137.	3.3	10
2	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Advances, 2021, 5, 176-184.	2.5	56
3	ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies. Leukemia and Lymphoma, 2021, 62, 1770-1773.	0.6	5
4	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	0.6	36
5	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	3.3	97
6	Impact of COVID-19 on healthcare organisation and cancer outcomes. European Journal of Cancer, 2021, 153, 123-132.	1.3	25
7	Myeloid malignancies with translocation t(4;12)(q11â€13;p13): molecular landscape, clonal hierarchy and clinical outcomes. Journal of Cellular and Molecular Medicine, 2021, 25, 9557-9566.	1.6	2
8	Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Advances, 2021, 5, 5258-5268.	2.5	12
9	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. Blood, 2021, 138, 3478-3478.	0.6	3
10	Spontaneous molecular response of IDH2 acute myeloid leukemia. Annals of Hematology, 2020, 99, 353-354.	0.8	1
11	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 421-428.	0.4	3
12	Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e986-e989.	0.2	3
13	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nature Cancer, 2020, 1, 965-975.	5.7	98
14	Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening. Gut Microbes, 2020, 12, 1800897.	4.3	38
15	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Cancer Discovery, 2020, 10, 1894-1911.	7.7	13
16	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	0.6	28
17	Bone marrow metastases mimicking acute leukaemia. British Journal of Haematology, 2019, 187, 556-556.	1.2	4
18	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature, 2019, 574, 273-277.	13.7	149

#	Article	IF	Citations
19	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673.	0.6	66
20	CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1,) Tj ETQq0 0 0 rgBT /Overlock 10 Cohort. Blood, 2019, 134, 1355-1355.	0.6	5
21	Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. Blood, 2019, 134, 3722-3722.	0.6	1
22	Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML. Blood, 2019, 134, 1416-1416.	0.6	5
23	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia, 2018, 32, 2008-2081.	3.3	18
24	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. Leukemia and Lymphoma, 2018, 59, 1742-1745.	0.6	6
25	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. Blood, 2018, 132, 993-993.	0.6	2
26	Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient. Infection, 2017, 45, 361-363.	2.3	10
27	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine, 2016, 22, 672-678.	15.2	301
28	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood, 2016, 127, 2451-2459.	0.6	198
29	The Role of Additional Sex Combs-Like Proteins in Cancer. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026526.	2.9	48
30	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	15.2	7
31	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
32	UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia and Lymphoma, 2016, 57, 199-200.	0.6	19
33	Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity. Blood, 2016, 128, 961-961.	0.6	6
34	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell, 2015, 27, 617-630.	7.7	449
35	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. American Journal of Hematology, 2015, 90, 859-863.	2.0	17
36	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	15.2	297

#	Article	IF	Citations
37	Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leukemia Research, 2015, 39, 818-821.	0.4	24
38	Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies. Journal of Medical Microbiology, 2015, 64, 676-681.	0.7	13
39	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. Journal of Clinical Investigation, 2015, 125, 1857-1872.	3.9	151
40	ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis. Blood, 2015, 126, 302-302.	0.6	2
41	Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma. Blood, 2015, 126, 3835-3835.	0.6	3
42	Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis. Blood, 2015, 126, 4-4.	0.6	4
43	Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica, 2014, 99, 201-203.	1.7	39
44	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. Blood, 2014, 124, 3734-3734.	0.6	38
45	AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model. Blood, 2014, 124, 3735-3735.	0.6	18
46	SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference. Blood, 2014, 124, 824-824.	0.6	2
47	SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS. Blood, 2014, 124, 525-525.	0.6	0
48	Clinical Features and Outcomes in Patients With Disseminated Toxoplasmosis Admitted to Intensive Care: A Multicenter Study. Clinical Infectious Diseases, 2013, 57, 1535-1541.	2.9	47
49	Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: A case-control study. American Journal of Infection Control, 2013, 41, 527-530.	1.1	13
50	Outcome of older patients with acute myeloid leukemia in first relapse. American Journal of Hematology, 2013, 88, 758-764.	2.0	49
51	EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D₃in acute myeloid leukemia cells. Cell Cycle, 2013, 12, 2978-2991.	1.3	39
52	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica, 2013, 98, 1711-1717.	1.7	41
53	Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities. Blood, 2013, 122, 1512-1512.	0.6	1
54	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). Blood, 2012, 120, 890-890.	0.6	1

#	Article	IF	Citations
55	Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010.. Blood, 2010, 116, 1083-1083.	0.6	8
56	Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens. Annals of Hematology, 2006, 85, 711-716.	0.8	11
57	An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica, 2006, 91, 1134-8.	1.7	16
58	Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma. Leukemia and Lymphoma, 2004, 45, 2481-2484.	0.6	11